These findings suggest that targeting of only one cytokine may be ineffective in suppressing cancer cachexia development, explaining why anti-TNFα and anti-IL-6 clinical trials failed to show a benefit with respect to tissue preservation and survival (33). Here, IL6 is linked to cancer.